Note to the businessman

Found results: 345

New trends in Silicon Valley and innovation

Ilya Strebulaev, Professor of Finance and Venture Capital at the Stanford Graduate School of Business, delivered a lecture on this topic at the Kazan IT Park the other day.

23.12.2016

Note to the businessman

The most active venture funds of 2016 have been identified

According to the results of the annual rating of the activity of venture funds in Russia, in 2016 the funds made 390 transactions – a quarter more than in the previous year.

19.12.2016

Note to the businessman

Three quarters of Russian venture capital

The return to stability, which the market has achieved after the decline in indicators over the years of economic turbulence, allows us to hope for its growth in the foreseeable future.

13.12.2016

Note to the businessman

The maturity of a billionaire

Wealthy people around the world manage to live longer and invest money in new life extension projects. How do they struggle with old age?

01.12.2016

Note to the businessman

Russian with Chinese – venture forever

The Russian-Chinese Investment Fund (RCIF) and the Chinese company Tus-Holdings have agreed to create a joint Russian-Chinese venture fund

07.11.2016

Note to the businessman

Biotechnology. Buy eternal life

Longevity-economy is being born before our eyes. Its boom will take place in the next 10-15 years, and this coincides with the planning horizon of venture funds.

20.10.2016

Note to the businessman

Investments-2016 (1st half of the year)

We present to your attention the "Overview of the direct and venture capital Investment Market for the first half of 2016, prepared by the Russian Venture Investment Association.

16.09.2016

Note to the businessman

Genetic tests in Russia

Not only end-users, but also corporations and states are interested in genetic technologies. What is the structure and prospects of the market for services related to genetic analysis?

06.09.2016

Note to the businessman

Immortality as an investment asset

In recent years, new classes of anti-aging investment assets have been formed, which can provide both high returns and radical life extension.

30.08.2016

Note to the businessman

Electroceutics

A new strategy perpendicular to pharmacology is being born before our eyes – bioelectric medicine, a very intriguing field and on the rise. The market volume will grow rapidly.

29.08.2016

Note to the businessman

Prospects for investments in biotech

Billions of dollars are already being invested in biotechnology. Let's try to figure out why people are already investing a lot of money in them today and what awaits us in the very near future.

22.08.2016

Note to the businessman

DNA testing in Russia

In recent years, genetic testing has become increasingly popular in the healthcare market. But in Russia, the state does not help to develop this direction in any way.

15.07.2016

Note to the businessman

In the coming years, humanity will have to find an answer to the question of how, without sacrificing safety and lowering strict regulatory standards, to prevent regression in the creation of new drugs.

22.06.2016

Note to the businessman

Additive technologies for medicine

The annual increase in additive manufacturing – growing objects using a 3D model - is 25%. The lion's share of this growth is accounted for by the medical and dental markets.

15.06.2016

Note to the businessman

Pharmaceutical business: Risk management

Merck has released the results of a survey on how to manage new risks associated with the changing landscape of the biopharmaceutical industry.

08.06.2016

Note to the businessman

How $4.5 billion turned into Nothing

Last year, the fortune of Elizabeth Holmes, who founded the biotech startup Theranos, was estimated at about $4.5 billion. Now Forbes has lowered the initial estimate to... zero.

02.06.2016

Note to the businessman

Perfluorane returns

Oleg Zherebtsov, the founder and former owner of the Lenta retail chain, and now CEO of Solopharm, decided to bring the legendary "blue blood" back to the market.

19.05.2016

Note to the businessman

Profit from immunotherapy – in 10 years

Cellular immunotherapy is unlikely to have a significant impact on the market of cancer drugs in the short term.

11.05.2016

Note to the businessman

Anti-aging – promising investments

The number of consumers in the Anti-Aging market is growing automatically and continuously, and in most countries they represent a wealthy category of the population.

06.04.2016

Note to the businessman

Rusnano revenues

According to the company's press center, Rusnano has demonstrated profit for the second year in a row, exceeding the figures of the previous year by more than two times.

25.03.2016